Modulation of angiotensin-converting enzyme by nitric oxide

Br J Pharmacol. 1998 May;124(2):291-8. doi: 10.1038/sj.bjp.0701836.

Abstract

1. The aim of the present study was to determine the effect of nitric oxide (NO) on angiotensin-converting enzyme (ACE) activity. 2. A biochemical study was performed in order to analyse the effect of the NO-donors, SIN-1 and diethylamine/NO (DEA/NO), and of an aqueous solution of nitric oxide on the ACE activity in plasma from 3-month old male Sprague-Dawley rats and on ACE purified from rabbit lung. SIN-1 significantly inhibited the activity of both enzymes in a concentration-dependent way between 1 and 100 microM. DEA/NO inhibited the activity of purified ACE from 0.1 microM to 10 microM and plasma ACE, with a lower potency, between 1 and 100 microM. An aqueous solution of NO (100 and 150 microM) also inhibited significantly the activity of both enzymes. Lineweaver-Burk plots indicated an apparent competitive inhibition of Hip-His-Leu hydrolysis by NO-donors. 3. Modulation of ACE activity by NO was also assessed in the rat carotid artery by comparing contractions elicited by angiotensin I (AI) and AII. Concentration-response curves to both peptides were performed in arteries with endothelium in the presence of the guanylyl cyclase inhibitor, ODQ (10 microM), and the inhibitor of NO formation, L-NAME (0.1 mM). NO, which is still released from endothelium in the presence of 10 microM ODQ, elicited a significant inhibition of AI contractions at low concentrations (1 and 5 nM). In the absence of endothelium, 1 microM SIN-1 plus 10 microM ODQ, as well as 10 microM DEA/NO plus 10 microM ODQ induced a significant inhibition on AI-induced contractions at 1 and 5 nM and at 1-100 nM, respectively. 4. In conclusion, we demonstrated that (i) NO and NO-releasing compounds inhibit ACE activity in a concentration-dependent and competitive way and that (ii) NO release from endothelium physiologically reduces conversion of AI to AII.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin I / metabolism
  • Angiotensin II / metabolism
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Animals
  • Carotid Arteries / drug effects
  • Carotid Arteries / enzymology
  • Diethylamines / pharmacology*
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology*
  • Guanylate Cyclase / antagonists & inhibitors
  • Male
  • Molsidomine / analogs & derivatives*
  • Molsidomine / pharmacology
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / enzymology
  • Nitric Oxide / blood
  • Nitric Oxide / pharmacology*
  • Oligopeptides / metabolism
  • Oxadiazoles / pharmacology
  • Peptidyl-Dipeptidase A / blood*
  • Quinoxalines / pharmacology
  • Rabbits
  • Rats
  • Rats, Sprague-Dawley

Substances

  • 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
  • Angiotensin-Converting Enzyme Inhibitors
  • Diethylamines
  • Enzyme Inhibitors
  • Oligopeptides
  • Oxadiazoles
  • Quinoxalines
  • Angiotensin II
  • hippuryl-histidyl-leucine
  • Nitric Oxide
  • linsidomine
  • Angiotensin I
  • diethylamine
  • Molsidomine
  • Peptidyl-Dipeptidase A
  • Guanylate Cyclase